Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Adamczak, Tomasz." wg kryterium: Autor


Wyświetlanie 1-3 z 3
Tytuł:
THE PRESCRIPTION TO OVER-THE-COUNTER SWITCHES AND DOUBLE REGISTRATION OF MEDICINES - THE PERSPECTIVE OF PHARMACISTS FROM THE GREATER POLAND.
Autorzy:
Zaprutko, Tomasz
Kopciuch, Dorota
Ratajczak, Piotr
Paczkowska, Anna
Adamczak, Olga
Kus, Krzysztof
Nowakowska, Elżbieta
Powiązania:
https://bibliotekanauki.pl/articles/895258.pdf
Data publikacji:
2019-10-30
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
pharmaceutical market
pharmacies
Rx-to-OTC switches
double registration
Opis:
The prescription to over-the-counter switch is a global occurrence. However, the switch phenomenon might be considered controversial. Nevertheless, the further development of switches seems to be inevitable, thus we collected pharmacists’ opinions about Rx-to-OTC switches including double registration of medicines. The study was conducted in pharmacies from the Greater Poland, using an anonymous questionnaire, which was delivered by direct contact. Finally, answers from 232 pharmacies were included in the study. Moreover, we analyzed data from 5500 Polish pharmacies, concerning the turnover of selected and doubly registered medicines. Rx-to-OTC switches were negatively evaluated by the majority (81.5%) of respondents. “Furaginum” was the most frequently chosen (60.8%) substance, which according to obtained answers should be available only on prescription. Study participants claimed that the most important drawback (chosen by 44.4% participants) of the double registration of medicines is the development of uncontrolled self-medication. Data obtained from a market research company revealed that the Rx-to-OTC switch may lead to the market share growth of OTC class (e.g. “furaginum”), but it is not the rule (e.g. “omeprazole/pantoprazole”). Although Rx-to-OTC switches are considered somewhat controversial, the switch, as well as double registration phenomenon, seems to be a subject of further development. However, in pharmacists opinion substances like “furaginum” should be available as an Rx-only brand instead of double registered medicine. In the case of Rx-to-OTC switches, additional information about possible side effects and/or interactions should be provided to the patients who might inappropriately use medicines.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 5; 907-912
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity
Autorzy:
Czub, Elzbieta
Nowak, Jan
Szaflarska-Poplawska, Anna
Grzybowska-Chlebowczyk, Urszula
Landowski, Piotr
Moczko, Jerzy
Adamczak, Daria
Mankowski, Przemyslaw
Banasiewicz, Tomasz
Plawski, Andrzej
Walkowiak, Jaroslaw
Powiązania:
https://bibliotekanauki.pl/articles/1039342.pdf
Data publikacji:
2014
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
: pyruvate kinase
calprotectin
inflammatory bowel diseases
ulcerative colitis
Crohn's disease
pediatrics
Opis:
Aims: Accurate assessment of inflammatory bowel disease (IBD) activity is the cornerstone of effective therapy. Fecal M2 isoform of pyruvate kinase (M2-PK) and fecal calprotectin (FC) are noninvasive markers of mucosal inflammation in IBD. The aim of this study was to compare performance of M2-PK and FC in assessment of pediatric ulcerative colitis (UC) and Crohn's disease (CD) severity and activity. Materials and methods: 121 patients with IBD, including 75 with UC and 46 with CD were recruited. Control group consisted of 35 healthy children (HS). Patients were assigned to groups depending on disease severity and activity. M2-PK and calprotectin concentration were determined in stool samples using ELISA. Areas under receiver operating characteristic curves (AUC) for FC and M2-PK with cut-off level at which M2-PK specificity was matching FC specificity were calculated and compared. Results: Performance of M2-PK at identifying patients with IBD, UC and CD among HS was inferior to FC. The differences in AUC were respectively: -0.10 (95% confidence interval [CI] [-0.13-(-0.06)], p<0.0001), -0.14 (95% CI [-0.19-(-0.09)], p<0.0001) and -0.03 (95% CI [-0.05-(-0.001)], p<0.02). M2-PK was inferior to FC in discriminating patients with mild UC from those with HS (AUC difference -0.23, 95% CI [-0.31-(-0.15)], p<0.0001). Conclusions: FC reflects pediatric IBD severity and activity better than M2-PK. This difference is particularly pronounced when identifying patients with mild UC and UC in remission.
Źródło:
Acta Biochimica Polonica; 2014, 61, 1; 99-102
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-3 z 3

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies